About the Study
Acanthamoeba corneal infections are difficult to treat and often require eyedrops for 6–12 months or longer. There is no clear consensus on the best treatment approach.Some doctors believe steroid eyedrops may help reduce inflammation and improve vision, while others worry steroids might prolong the infection. This study aims to find out whether steroid eyedrops are safe and effective when used to treat acanthamoeba infections.
What's Involved
Eligibility Criteria
- Age 8 years or older, except for 16 years or older in the UK
- Diagnosed with acanthamoeba keratitis (AK) confirmed by lab testing or confocal microscopy
- Ocular inflammation after 1 month of anti-amoeba treatment
Cannot join if you have:
- Herpetic or fungal keratitis
- Corneal perforation or prior corneal transplant for AK
- No light perception vision in the affected eye
- Allergy or hypertensive reaction to corticosteroids
- Currently taking systemic corticosteroids
A study doctor will confirm eligibility during screening.
Required Visits and Procedures
- You will use an eyedrop for acanthamoeba for 1 month.
- After that, if still eligible, you’ll be randomized (like a coin flip) to receive either a steroid eyedrop or a lubricating eyedrop.
- You’ll take this study eyedrop for 2 months while continuing the anti-amoebic eyedrop.
- Follow-up visits: 1 month, 6 weeks, 2 months, 3 months, 6 months, and 12 months.
- Each visit lasts about 2 hours and includes eye imaging and vision testing.
Possible Benefits
- Free anti-amoeba medication (normally not covered by insurance)
- Access to an effective eyedrop, not yet available in the U.S.
- Close monitoring with advanced imaging by experienced ophthalmologists
- Helping future patients by contributing to better treatment research
Learn More
📄 View the Patient Information Sheet (PDF)
🔗 View study details on ClinicalTrials.gov
Contact the UCSF Study Team
For more information, contact your nearest enrollment center or the coordinating center (UCSF).
Dr. Jeremy Keenan, MD MPH
UCSF Department of Ophthalmology, Proctor Foundation
📧 [email protected]
☎️ (415) 476-6323
Dr. Gerami Seitzman, MD
UCSF Department of Ophthalmology, Proctor Foundation
📧 [email protected]
☎️ (415) 476-1442
Enrollment Centers
Site Information
| Institution | Site Investigators | Contact Information | City | Country |
|---|---|---|---|---|
| University of California, San Francisco | Jeremy Keenan MD Gerami Seitzman MD | San Francisco | USA | |
| Oregon Health & Science University | Roma Pegany MD | [email protected] | Portland | USA |
| University of Illinois, Chicago | Elmer Tu MD Maria Soledad Cortina MD | Chicago | USA | |
| University of Florida | Sonal Tuli MD | [email protected] | Gainesville | USA |
| University of Pittsburgh | Gaurav Prakash MD | [email protected] | Pittsburgh | USA |
| University of Miami | Guillermo Amescua MD | [email protected] | Miami | USA |
| Columbia University | Leejee Suh MD | [email protected] | New York | USA |
| University of Pennsylvania | Bennie Jeng MD | [email protected] | Philadelphia | USA |
| Johns Hopkins University | Nakul Shekhawat MD | [email protected] | Baltimore | USA |
| University of Iowa | Mark Greiner MD | [email protected] | Iowa City | USA |
| University of Washington | Minh Nguyen MD | [email protected] | Seattle | USA |
| Baylor College of Medicine | Alejandro Arboleda MD | [email protected] | Houston | USA |
| Universidade Federal de Sao Paulo | Denise de Freitas MD | [email protected] | São Paulo | Brazil |
| Aravind Eye Care System - Madurai | N. Venkatesh Prajna MD | [email protected] | Madurai | India |
| Aravind Eye Care System - Coimbatore | Revathi Rajamaran | [email protected] | Coimbatore | India |
| Moorfields Eye Hospital | Su-yin Koay MD | [email protected] | London | England |
The study in this website was supported by the National Eye Institute of the National Institutes of Health under Award Number UG1EY033284. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.